Mediar Therapeutics wants to stop the scar makers

Three hospital research programs became one biotech with a shared suspicion: fibrosis might be interrupted where scar tissue is made. Now Mediar is testing that idea in lungs, skin and kidneys - with Lilly and Ono taking an interest.